October 22, 2012
Up 45% in 2012 and nearly 70% in the past 12 months, Danish pharmaceutical company Novo Nordisk (NYSE: NVO ) has outpaced its peers by a wide margin. Novo's performance has been fueled by an incredibly concerning trend, the growing incidence of diabetes worldwide. As the leader in insulin -- a must-have for Type 1 diabetes patients and a growing need for many Type 2 diabetics -- the company is well-positioned to capitalize on this secular trend.
In the following video, health care bureau chief Brenton Flynn and analyst David Williamson discuss some more positive news for Novo Nordisk, as well as an important date for investors to be aware of next month.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.